Cumulative Index 1999

VOLUME 11

March	UTILIZATION OF TECHNOLOGY: UNREALIZED POTENTIAL, pages 1–120
June	EVIDENCE-BASED NURSING PRACTICE, pages 121–296
September	INTERVENTIONAL CARDIOLOGY, pages 297–408
December	LUNG FAILURE ACROSS THE LIFE SPAN, pages 409–542

Note: Page numbers of article titles are in **boldface** type.

Abciximab (ReoPro), research and, 357–360
ABG. See *Arterial blood gas (ABG)*.
Acolysis catheter, for thrombus removal, 320–321
Acute lung injury (ALI), diagnostic criteria for, 452–453
  prevention of, 452–453
Acute respiratory distress syndrome (ARDS), assessment data in, integration of, 236–237
  definition of, 519
  description of, 233
  diagnostic criteria for, 452–453, 519
  extracorporeal membrane oxygenation in, 243–245
  exudative phase of, 236
  fibrotic phase of, 237
  fluid shifts in, 235–236
  hemodynamic monitoring in, 238–239
  in children, **519–528**
    agitation of, analgesia and sedation in, 527
      assessment of, 525–526
    analgesia and sedation in, 525–526
    arterial blood gases in, 521
    cardiovascular system and tissue oxygenation in, 521
    diagnostic criteria for, 519–520
    family support and, 526
    fluid and electrolyte balance in, 525
    management of, 521–528
      supportive, 525–527
      therapeutic, 521–525
    nutrition in, 525
    oxygenation variables and, 521
    physical examination in, 521
    thermoregulation in, 525
  management of, **233–247**
  management strategies for, 237–238
  mediators of, 234–235
  mortality from, 233
  nitric oxide in, inhaled, 245
  pathophysiology of, 233–236, 519–520
  patient positioning in, continuous lateral rotation therapy for, 241
    prone, 241–243
  positive end-expiratory pressure in, 239–240
  pressure-controlled inverse ratio ventilation in, 240–241
  prevention of, 452–453
  proliferative phase of, 236–237
  risk factors for, 233–234
ACV. See *Assist-control ventilation (ACV)*.
Adenosine diphosphate receptor antagonist(s), 356–357
  clopidgrogel, 365–366
  clopidogrel, 365–366
  ticlopidine, 364–365
Advanced Life Support evaluation, in severe head trauma, 212
Advanced practice nurse. See also *Clinical nurse specialist (CNS)*.
  on progressive pulmonary care unit, for ventilator-dependent patient, 250–251
Advanced registered nurse practitioner (ARNP), financial impact of, 279
  impact on health care team, 279
  implementation in acute care setting project, contributions to patient care, 280–281
    discharge process and, 280
    length of stay and, 280
    patient satisfaction and, 280–281
  quality of care and, 279
  role of, definition of, 278–279
    implementation in acute care setting project, **277–282**
    literature review of, 278–279

Aggrastat (tirofiban). See *Tirofiban (Aggrastat)*.
Airway management, artificial, advances in, **7–17**
  patient-ventilator interaction for, 15
  reduction of aspiration risk in, 9–10
  reduction of intraluminal mucus and biofilm formation in, 10–11
  strategies for, 8–10
  tracheal tubes in, 7–8
    complications with, 8
  tube cuff injuries in, avoidance of, 11–13
  work of breathing in, decrease in, 13–15
Airway pressure release ventilation, in infant and child, 505–506
Airway pressures, in mechanical ventilation, minimization of, 449–450
  plateau pressure in, 450
AIS (acute ischemic stroke), recombinant tissue plasminogen factor for, 262–263
Albuterol, for asthma, in child, 515
ALI. See *Acute lung injury (ALI)*.
AMIGO (Atherectomy before MultiLink Improves Lumen Gain Outcome) trial, 313
Amiodarone, for ventricular tachycardia, 378
Analgesia, in head injury, 218
Anemia, pulse oximetry and, 91
  interpretation of, 93
Angina, percutaneous transluminal myocardial revascularization for, 327–328
Angiogenesis. See *Gene therapy*.
Angiography. See *Coronary MR angiography*.
Angiotensin II receptor antagonists, in heart failure management, 128
Angiotensin-converting enzyme (ACE) inhibitor, in heart failure management, 125
  up-titration algorithm for, 132–133
Antiarrhythmic therapy, for lethal tachyarrhythmias, 303
  in heart failure management, 128
Antiarrhythmics Versus Implantable Defibrillator (AVID) study, in ventricular tachycardia, 378–379
  in elderly, 379
Antibiotic prophylaxis, postcardiac surgery, 162, 165
Anticoagulant drug(s), dalteparin (Fragmin), 367–369
  enoxaparin (Lovenox), 366–367
  heparins, 357
  in heart failure management, 129
  nursing considerations with, 360–361
  warfarin (Coumadin), 357
Anticoagulation, in interventional cardiology, 144, 152, 154
Antiplatelet drugs, adenosine diphosphate recetor antagonists, 356–357, 364–366
  categories of, 356–357
  glucoprotein IIb/IIIa antagonists, 357–364
  in heart failure management, 129
  in interventional cardiology, 152, 154
  nursing considerations with, 360–361
Arachadonic acid, in acute respiratory distress syndrome, 235
ARDS. See *Acute respiratory distress syndrome (ARDS)*.
Arginine, in support of gastrointestinal tract, 229
ARNP. See *Advanced registered nurse practitioner (ARNP)*.
Arrhythmia, implantable cardioverter defibrillators in, 305–306
  monitoring system alarms for, 79–80
Arterial blood gas (ABG), measurement of, capnography *versus*, 54, 56–57, 60
  pulse oximetry *versus*, 96
Aspiration, causes of, 8
  detection of, early, 10
  risk for, reduction of, 8–10
Assist-control ventilation (ACV), in infant and child, 502–504
  in respiratory failure, post-ICU care transitioning and, 484
Asthma. See also *Status asthmaticus*.
  acute episode, clinical findings in, 512–513
  description of, 512
  in children, clinical assessment in, 514
    incidence and etiology of, 511–512
    life-threatening respiratory failure in, intubation and mechanical ventilation for, 516
    medications with long-term control, 515
    risk factors for life-threatening, 512
  pathophysiology of, 512–514
  pharmacotherapies for, advanced, 515–516
    standard, 514–515
  status asthmaticus and impending respiratory failure in, **511–518**
  triggers for, 514
Atherectomy before MultiLink Improves Lumen Gain Outcome (AMIGO) trial, 313
AVID. See *Antiarrhythmics Versus Implantable Defibrillator (AVID) study*.

Balloon *versus* Optimal Atherectomy trial (BOAT), 312–315, 333
Barbiturates, in severe head injury, 221
Barotrauma, in mechanical ventilation, 447–448
Beta Energy Restenosis Trial (BERT), 321
Bile, immunologic function of, 228
Bilevel positive airway pressure ventilation, in infant and child, 505–506
β-Blockers, in heart failure management, 126
Blood transfusions, post minimaly invasive direct coronary artery bypass surgery, 183
BOAT. See *Balloon versus Optimal Atherectomy Trial (BOAT)*.
Boston Scientific Radius stent, 319
Brachytherapy. See also *Intraluminal radiation therapy*.
  for restenosis, **333–348**
Bradykinin, in acute respiratory distress syndrome, 234
Breathing in the intensive care unit, **409–422**
Bronchodilators, for asthma, in child, 514–515

CABG (coronary artery bypass surgery). See also *Minimally invasive direct coronary artery bypass (MIDCAB)*.
  via median sternotomy, 177–178
Calcium channel blockers, in heart failure management, 128
CAP, Community-acquired pneumonia (CAP)
Capnography
  accuracy of, 50–51
  advantages of, 49
  an underutilized technology, **49–62**

clinical applications of, 52–58
combination with pulse oximetry, 102–103
cost and use justification of, 58–60
cost savings with, in futile resuscitation avoidance, 59–60
in intubation liability prevention, 59
in reduction of arterial blood gasses, ventilation/perfusion scans, pulmonary angiography, 60
description of, 426–427
during cardiopulmonary arrest, 53–56
during endotracheal tube placement, 52
during nasogastric tube placement, 52–53
in arterial Co_2 prediction, 54, 56–57
in end expiration identification, during hemodynamic wave form analysis, 58
in pulmonary emboli detection, 57–58
limitations of, 49
measurement techniques in, 50–51
monitors in, 427
normal carbon dioxide waveform in, 428
physiologic deadspace and, identification of, 57
physiology of, 49–50
recordings in, real-time, 428, 430
slow-speed, 428–429
response to drug therapy in, 428, 431
safety of, 51–52
sampling technique in, 426–427
versus arterial blood gas measurement, 54, 56–57
CAPRIE (Clopidogrel *versus* Aspirin in Patients at Risk for Ischemic Events) trial, 365–366
Cardiac disease, CardiAction program against, 184–185
Cardiac index/output (CO/CI), from pulmonary artery catheterization, 23, 25
Cardiac output, assessment of, 238–239
inotropics for, 238
Cardiac surgery, antibiotic prophylaxis and, reduction of, 162, 165
Cardiac Value Enhancement Project: Strong Memorial Hospital, cost savings of, 171
hospital-wide commitment to, 165
lab test reduction in, 165, 171
length of stay in, 165, 171
Care Value Enhancement Project: Strong Memorial Hospital, care map evolution in, 165–167
outcome management and, variance data collection tool and, 172–173
outcome management team, 165, 174
potassium and magnesium supplementation protocol, 165, 170
preprinted orders for, 165, 168–170
early extubation following, 160
barriers to, 162
decreased time for, 160–161
fast-track initiative for, 160–162
keys to success of, 162
pain management and, 160
fluid resuscitation following, fast-track protocol for, 162, 164
fast-track team and, 162, 163
perspective on, 159–160
rapid progression following, **159–175**
ventilator weaning and, short-term protocol, 163
CardiAction program, against cardiac disease, 184–185
Cardiography. See *Impedance cardiography*.
Cardiology. See *Interventional cardiology*.
Cardiopulmonary arrest, capnography in, 53–56
Cardiothoracic heart surgery, ventilator dependence following, 250
Care pathway(s), diagnosis-specific, 143
in heart failure, 136–138
Carotid endarterectomy (CEA)
clinical pathway for, **189–208**
anesthesia and, 206
comorbidities and, 206
diagnostics in, 198, 200
discharge instructions in, 190, 197
exclusion criteria in, 206
initial development of, 190–197
modification of, 190
MR angiography in, 200
outcomes with, in critical care setting usage, 204–205
in patient care changes, 205–206
patient plan in, 190, 196
radiographs in, 198
targets of, laboratories, 190, 198
ultrasound in, 199–200
hemodynamic monitoring in, 204–205
length of stay for, 199–202
literature review of, 189–190
neurologic monitoring in, 204–205
outcomes with, 199–206
in length of stay, 199–202
in patient satisfaction, 203–204
study population and methods, 199–200
teleform variance analysis collection tool for, 206–207
unplugging the mystery of patient care in, **189–208**
CAVEAT (Coronary Angioplasty *versus* Excisional Atherectomy Trial), 312–313, 333
CEA. See *Carotid endarterectomy (CEA)*.
Central venous pressure (CVP), from pulmonary artery catheterization, 23–24
Cerebral perfusion pressure (CPP), in severe head injury, 210, 215, 217
management of, 217–218
Chronic obstructive pulmonary disease (COPD), ventilator dependence in, 249
Clinical nurse specialist (CNS). See also *Advanced practice nurse*.
effect of, on complications, 271, 274
on health care cost, 272
on health care utilization, 271–272
on length of stay, 270–271, 273–274
on mortality rate, 272
historical role of, 270
patient outcomes and, **269–275**
literature review of, 270–272
orthopedic unit study of, 272–279
Clopidogrel bisulfate, anticoagulation with, post stent, 318
Clopidogrel *versus* Aspirin in Patients at Risk for Ischemic Events (CAPRIE) trial, 365–366
Closed-suction system, in ventilator-associated pneumonia, 419
CLRT (continuous lateral rotation therapy), 241
CNS. See *Clinical nurse specialist (CNS)*.
CO/CI (cardiac index/output), from pulmonary artery catheterization, 23, 25
Community-acquired pneumonia (CAP), American Thoracic Society guidelines and, 413
clinical pathways for, 414
definition of, 409

Community-acquired pneumonia (CAP), American Thoracic Society guidelines and (*Continued*)
diagnosis of, 409, 411
discharge criteria in, 411
indications for hospitalization in, 411
interventions in, 414
outcomes in, 413–414
prevention of, 414
risk factors for hospitalization in, 411
prediction model for, 412–413
treatment of, 410–411
Congestive heart failure, ventilator dependence in, 250
Continuous airway pressure, monitoring of, 428, 431–433
equipment for, 431
neuromuscular blockade in, 431–432
waveform in, 431–433
Continuous lateral rotation therapy (CLRT), in acute respiratory distress syndrome, 241
in ventilator-associated pneumonia, 419
Continuous mixed venous oxygen (Svo_2) monitoring, accuracy of, 33–34
advantages of, 38–39
arguments against, 44
case histories in, 39–40, 42–43
clinical applications of, and associated physiology, 34–37
controversy in, 33
controversy with, 33
cost issues with, 44
versus pulmonary artery catheterization, 44
description of, 34
determination of, by tissue extraction of oxygen, 34–35
expensive or indispensible, **33–48**
fiberoptic technology in, 33–34
manufacturer's claims for, 34
normal Svo_2 values and, 34, 37
physiology of, 35–37
resource utilization reduction with, 45
safety of, 33
Svo_2 levels in, as indicator of threat to tissue oxygenation, 39–40
as prognostic indicator, 43–44
comparison with other parameters, 38–44
decrease in, 34, 37
detection of changes in oxygen consumption, 43
differentiation of changes in arterial and tissue oxygenation, 41–43
intrapulmonary shunting measurement and, 40–41
lactate level correlation and, 38
pulmonary venous return and, 34, 36
tissue oxygenation and, 37–38
Continuous pulmonary assist pressure, in respiratory failure, post-ICU care transitioning and, 485
Control mode ventilation, in infant and child, 503, 504
COPD (chronic obstructive pulmonary disease), ventilator dependence in, 249
Coronary Angioplasty *versus* Excisional Atherectomy Trial (CAVEAT), 312–313, 333
Coronary artery bypass grafting (CABG). See also *Minimaly invasive direct coronary artery bypass (MIDCAB)*.
MR coronary angiography following, 393–396
via media sternotomy, 177–178
Coronary artery disease, incidence and cost of, 383
Coronary MR angiography, coronary artery anatomy and, 384–396
coronary stents and, 395
current techniques, echo planar imaging, 386
MR subtraction methods, 386
three-dimensional, 385–386
two-dimensional, k-space gradient-echo, 384–385, 387–388
early attempts in, 384
for coronary artery stenosis, 389–393
future perspectives in, atherosclerotic plaque imaging, 399
contrast media with, 399–400
respiratory motion artifact suppression, 399
in blood flow and flow reserve assessment, 396, 398–399
after pharmacologic vasodilation, 398–399
phase contrast approach in, 398
time-of-flight in, 398
of anomalous coronary arteries, 388–389
of normal coronary arteries, 386–388
post cardiac surgery, 396
post coronary artery bypass grafting, 393–398
technical limitations of, 384
Corticosteroids, for asthma, in child, 515
Cost, in acute and critical care, outlier-driven, 107–108
of health care, clinical nurse specialist effect on, 272
CPP. See *Cerebral perfusion pressure (CPP)*.
Critical care unit, for heart failure patient, 129–130, 132–133
CVP (central venous pressure), from pulmonary artery catheterization, 23–24

Dalteparin (Fragmin), 367–369
DCA. See *Directional coronary atherectomy (DCA) catheter*.
Decannulation, of ventilator-dependent patient, 253–254
Defibrillators, internal. See also *Implantable cardioverter defibrillators (ICDs)*.
internal, evolution of, **303–310**
Desquamation, gastrointestinal, immunologic function of, 228
Diabetes mellitus, carotid artery endarterectomy and, 206
Digoxin, in heart failure management, 125
Directional coronary atherectomy (DCA), clinical trials of, 312–313
description of, 312
FDA approval of, 311
vs. percutaneous transluminal coronary angioplasty, 312
Directional coronary atherectomy (DCA) catheter, clinical trials of, 312–313
description of, 312
FDA approval of, 311
for restenosis, 311–313
restenosis following, 313
vs. percutaneous transluminal coronary angioplasty, 312
Discharge process, advanced registered nurse practitioner role in, 280
Dissection, in percutaneous transluminal coronary angioplasty, 311

Diuretics, in heart failure management, 125–126
Diversional activities, for ventilator-dependent patient, 252

$ECco_2R$. See *Extracorporeal carbon dioxide removal ($ECco_2R$)*.
ECMO. See *Extracorporeal membrane oxygenation (ECMO)*.
Education, outcomes-based in a critical care nursing course, **283–290**
Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial, 367
ELCA (excimer laser coronary angioplasty), 317
Electrocardiographic monitoring, post minimaly invasive direct coronary artery bypass surgery, 183
Electrolarynx, for ventilator-dependent patient, 251–252
Electrophysiology (EP) studies, for syncope evaluation, 298
  in ventricular tachycardia/ventricular fibrillation, 376–377
Elevation of head of bed, in severe head injury management, 217
Emergency department, for heart failure patient, 131–133, 136–137
Emergency department stroke team. See also *Stroke team, emergency department*.
  for treatment with recombinant tissue plasminogen factor (rt-PA), **261–268**
    case example, 261–262
    evolution of, 263–267
Endotracheal tubes, placement of, capnography in, 52
Endotracheal tubing, in ventilator-associated pneumonia, 419, 420
End-tidal carbon dioxide monitoring, capnography in, 426–430
ENoxaparin and TIClopidine after Elective Stenting (ENTICES) trial, 366–367
Enoxaprin (Lovenox), 366–367
Enteral feedings, as risk factors, in ventilator-associated pneumonia, 420
Enteral nutrition, early, after surgery, **227–231**
  in elective bowel surgery patients, 230–231
  role in critical illness, 229–230
ENTICES (ENoxaparin and TIClopidine after Elective Stenting) trial, 366–367
EPIC (Evaluation of c7E3 for the Prevention of Ischemic Complications) trial, 358
EPILOG (Evaluation of PTCA to Improve Longterm Outcome by c7E3 GP IIb/IIIa Receptor Blockages) trial, 358
EPISTENT (Evaluations of IIb/IIIa Platelet Inhibition for Stenting) trial, 358–359
Eptifibatide (Integrilin), 362–364
ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events) trial, 367
Ethical dilemmas, outliers and, 109–110
Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial, 358
Evaluation of PTCA to Improve Longterm Outcome by c7E3 GP IIb/IIIa Receptor Blockages (EPILOG) trial, 358
Evaluations of IIb/IIIa Platelet Inhibition for Stenting (EPISTENT) trial, 358–359
Evidence-based nursing practice, definition of, 159
Excimer laser coronary angioplasty (ELCA), 317
Exercise, in heart failure management, 127
Extracorporeal carbon dioxide removal ($ECco_2R$), as lung protective stratey, 451
  in acute respiratory distress syndrome, in child, 523–524
Extracorporeal membrane oxygenation (ECMO), in acute respiratory distress syndrome, 243–245
  in child, 523–524
  in mechanical ventilation, in infant and child, 507
Extubation, early, postcardiac surgery, 160–162
  post minimaly invasive direct coronary artery bypass surgery, 183

FANTASTIC (Full Anticoagulation *versus* Aspirin and Ticlopidine) trial, 364
Femoral pseudoaneurysm, postprocedure, 144
Femoral sheaths, in interventional cardiology, 153
  training registered nurses to remove, 154
Fever, in head injury, 217
Flu shot, for pneumonia candidates, 414
Fluid management, in status asthmaticus, in child, 516
Fluid resuscitation, postcardiac surgery, 162, 164
Forced inspiratory oxygen (FIo_2), pulse oximetry and, 95
Fragmin (dalteparin). See *Dalteparin (Fragmin)*.
Full Anticoagulation *versus* Aspirin and Ticlopidine (FANTASTIC) trial, 364

Gastric acid, immunologic function of, 228–229
Gastrointestinal tract. See also *Enteral feeding*.
  bacterial translocation via, 229
  enteral nutrition and, 229–230
  functions of, immunologic, 228–229
    normal, 227–228
  nutrient support of, 229
GCS (Glasgow Coma Scale), in severe head injury, 211
Gene therapy, **349–353**
  administration of, 351–352
    post procedure monitoring and, 352
  angiogenesis with, 350–351
  background of, 349–350
  basic concepts of, 350
  early studies in, 350
  follow-up procedures, 352
  for cardiovascular disease, **349–353**
  gene delivery into cells, 350
  side effects of, 352
Glasgow Coma Scale (GCS), in severe head injury, 211
Glutamide, in support of gastrointestinal tract, 229
Glycoprotein IIb/IIIa antagonist(s), 357
  abciximab (ReoPro), 357–362
  epifibatide (Integrin), 362–364
  tirofiban (Aggrastat), 360–362
Gut-associated lymph tissue, immunologic function of, 228–229

HAP. See *Hospital-acquired pneumonia (HAP)*.
Head injury. See also *Severe head injury*.
from blunt or penetrating trauma, 210
secondary, 210–211
Health care, cost of, clinical nurse specialist effect on, 272
utilization of, clinical nurse specialist effect on, 271–272
Health care overview, evidence-based nursing practice and, 159
Heart failure, chronic advanced, characterization of, 121
exercise for, 127
incidence of, 121
mortality rate in, 122
nonpharmacologic approaches to, 124, 127
patient education and compliance in, 124, 127
pharmacologic approaches to, 124–129
chronic left ventricular, characterization of, 121
guidelines for evaluation and care of, 124
disease state management of, programs for, 122–124
rapid response time in, 139
survival and life quality outcomes and, **121–141**
management settings for, critical care, 129–130, 132–133
emergency department, 131–133, 136–137
nontraditional, 134–135
outpatient, 130–131, 134–135
palliative and hospice, 137–39
short-stay unit, 131–133
subacute care, 131, 137, 138
manipulation of survival and life quality outcomes in, **121–141**
Helium gas with oxygen, for status asthmaticus, in child, 515
Hemodynamic monitoring, **19–31**
advances in continuous, noninvasive, **63–75.** See also *Impedance cardiography*.
minimaly invasive direct coronary artery bypass surgery and, 181
of carotid artery endarterectomy patients, 204–205
technical aspects of, 26–27
utilization of, education for, 27–28
Hemodynamics, in acute respiratory distress syndrome, 238–239
HFV. See *High-frequency ventilation (HFV)*.
High-frequency oscillatory ventillation, in infant and child, 505–506
High-frequency ventilation (HFV), as lung protective strategy, 451
in acute respiratory distress syndrome, in children, 523
in infant and child, 505–506
in neonatal respiratory failure, controversy regarding, 494–495
patient care with, 495
traditional usage of, 495
types of, 494
Histamine, in acute respiratory distress syndrome, 234
Home care teaching, for ventilator-dependent patient, 254–257
Hospice care, in end-stage heart failure, 137–139
Hospital-acquired pneumonia (HAP), 414–416
aspiration-induced, 416
best practices in, 416
classification of patients with, 415–416
critera for, 415
definition of, 14–15, 414–415
diagnosis of, 415
outcomes in, 415
patients at risk for, 415
prevention of, 416
severe, definition of, 415, 418
treatment of, 415, 417
antibiotics in, 417
Human immunodeficiency virus (HIV) disease, epidemiology of, 455
in children, incidence of, 455
pulmonary problems in, 456–457
transmission of, 455–456
in women, 455
respiratory complications of. See also *named pathology, e.g., Pneumocystis carinii pneumonia*.
bacterial pneumonia, 462
lymphoid interstitial pneumonia, 462–463
mycobacterium tuberculosis, 461–462
Pneumocystic carinii pneumonia, 457–461
pulmonary lymphoid hyperplasia, 462–463
respiratory complications through the life span, **455–464**
Hydralazine-nitrates combination, in heart failure management, 126–127
Hypercapnia, in severe head injury, 211
Hyperemia, in severe head injury, 211
Hyperventilation, in severe head injury, 219–220
Hypothermia, in severe head injury, 221–222

ICDs. See *Implantable cardioverter defibrillators (ICDs)*.
IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) trial, 363
Impedance cardiography, accuracy and safety of, 66–68
applications of, 68, 70–71
clinical integration and economic considerations with, 72–73
comparison of bolus thermodilution with Fick technique and, 66–68
comparison with other methods, 67–69
cost savings with, 72–73
costs of, direct, 72
devices for, 65–66
efficacy of, 66–68
electrode placement in, 64
for abnormal O wave, 70
hemodynamic parameters, definitions, normal values in, 64, 66
impact of, 71–72
in coronary artery disease screening, 70
in heart failure, emergency room management of, 68, 70
in operating room assessment, 70
in outpatient and home care, 68
in pregnant patient, 70–71
overview of, 64–66
pediatric, 71
techniques in, 65–66
Impedance monitoring, basis of, 432
description of, 432–433
history of, 432–433

Implantable cardioverter defibrillators (ICDs), first generation, 303–304
future of, diagnostic capabilities, 308–309
new applications, 307
system innovations, 307–308
in ventricular tachycardia, 378–380. See also *Antiarrhythmics Versus Implantable Defibrillator (AVID) study*.
cost-effectiveness of, 381
indications for, 307–308
insurance coverage for, 306–307
second generation, 304
third generation, 304–305
arrhythmia detection with, 305–306
electrogram storage in, 306
generators in, 306–307
lead systems of, 306
tiered therapy with, 304–305
Implantable loop monitor. See *Reveal insertable loop recorder; Reveal insertable loop recorder (RILR) system*.
Implantable loop recorder (ILR), **297–301.** See also *Reveal Insertable loop recorder (RILR) system*.
Inotropic agents, for cardiac output, 238
in heart failure management, 128–129
Integrilin (eptifibatide). See *Eptifibatide (Integrilin)*.
Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis (IMPACT) trial, 363
Intermittent mandatory ventilation, in infant and child, 503–504
in respiratory failure, post-ICU care transitioning and, 484–485
Interstitial pulmonary disease, ventilator dependence in, 249–250
Interventional cardiology, evidence-based clinical outcome management in, **143–157**
anticoagulation in, 144, 152, 154
antiplatelet therapy in, 152, 154
clinical pathways in, computerized, 156–157
Day of Angioplasty Procedure Admission in, 154–155
day-of-procedure admission program in, 154–155
discharge planning in, 155
literature review of, 143–144
variance analysis of, 156
variance analysis sheet in, 152
vascular complications and, 144
hematoma management in, with and without arterial sheath placement, 153
intracoronary stent clinical pathway, 145–151
Rochester General Hospital study, **143–157**
vascular complications of, risk factors for, 144
Interventional device(s), excimer laser coronary angioplasty catheter, 317
for intraluminal radiation, 321–323
for problem lesions, 315–317
for restenosis, directional coronary atherectomy, 311–313
Palmaz-Schatz stent, 312–313, 317–320, 333–334
prevention of, 322
for thrombus removal, 320–321
research in, past decade, **311–325**
rotational atherectomy catheter, 315–316
transluminal extraction catheter, 316–317
Intimal hyperplasia, in restenosis, post angioplasty, 313
Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial, 364
Intracranial hypertension, management of, 215–216
Intracranial pressure (ICP), in severe head injury, 210
Intraluminal radiation therapy, current modalities in, 338–339
dose/dose-rate effect in, 336
education for, 342
genesis of, 334
liquid/gas-filled balloons, 340
local delivery, 340
procedure for, 338–339
coordination of, 341–342
quality assurance and, 341
radiation decay and, 336
radiation sources in, 336
investigational, 337–338
radioactivity and, 335–336
safety of, 340–341
seed train in, 339
stents in, radioactive, 339–340
team for, 342
Intrapulmonary shunting (Qs/Qt), mixed venous oxygen level monitoring and, 40–41
pulse oximetry assessment of, 94–95
Intubation, esophageal, during endotracheal tube placement, 52
in head trauma, 212, 214
endotracheal, 214
oral, 214
sedation and pharmacologic paralysis for, 214
liability prevention for, 59
tracheal, during nasogastric tube placement, 52–53
ISAR (Intracoronary Stenting and Antithrombotic Regimen) trial, 364
Ischemic heart disease, adjunctive therapy for, **355–371**
anticoagulant drugs, 357, 366–369
antiplatelet drugs, 356–366
description of, 355
Isotonic crystalloid solutions, in head trauma, 214

Large intestine, function of, normal, 228
Laser(s). See *Percutaneous transluminal myocardial revascularization (PTMR)*.
Legionella, in bronchitis *vs.* pneumonia, 411
infection risk from, 416
Length of stay (LOS), advanced registered nurse practitioner role in, 280
clinical nurse specialist effect on, 270–271, 273–274
for carotid artery endarterectomy, 199–202
for minimaly invasive direct coronary artery bypass surgery, 183
in interventional cardiology, 144, 154, 155
Lipid-lowering agents, in heart failure management, 129
Liquid ventilation, as vehicle, for debris removal from pulmonary system, 496
for medication delivery, 496
complications of, 496
family support and education for, 496
in acute respiratory distress syndrome, in child, 524–525

Liquid ventilation (*Continued*)
partial, 496
in mechanical ventilation, in infant and child, 507
perfluorocarbon fluid in, 495
tidal, 495
Long-term care facilities, for ventilator-dependent patient, 254
Long-term mechanical ventilation (LTMV), definition of, 465
weaning pathways and protocols for. See also *Weaning, from long-term mechanical ventilation*.
case study of, 467
definitions of, 467–468
weaning pathways and protocols in, **465–479**
Loop monitor(s), external, 297–298
implantable, **297–301**
LOS. See *Length of stay* (*LOS*).
Lovenox (enoxaparin). See *Enoxaprin* (*Lovenox*).
LPV. See *Lung protective ventilation* (*LPV*) *strategy*(*ies*).
LTMV. See *Long-term mechanical ventilation* (*LTMV*).
Lung protective ventilation (LPV) strategy(ies), 448–452
airway pressure and volume minimization, 449–451
Lung protective ventilation (LVP) strategy(ies), extracorporeal carbon dioxide removal, 451
high-frequency ventilation, 451
objectives of, 449
oxygen supply and demand optimization, 449
permissive hypercapnia, 450–451
postive end-expiratory pressure, 451–452
pressure control ventilation, 451

MADIT (Multicenter Automatic Defibrillator Implantation Trial), 380–381
Magnesium sulfate, for status asthmaticus, in child, 515–516
Mannitol, in head-injured patients, 219
Mechanical ventilation. See also *Long-term mechanical ventilation* (*LTMV*).
acute lung injury from, diagnostic criteria for, 453
prevention of, 452–453
acute respiratory distress syndrome from, diagnostic criteria for, 453
prevention of, 452–453
complications of, barotrauma and volutrauma, 447–448
oxygen toxicity, 447
systemic inflammation and infection, 448
in acute respiratory distress syndrome, 239–241
in children, 521
in asthma, in child, 516
in infant and child, adjuncts to, 506–508
airway pressure release, 505–506
assist-control, 502–504
bilevel positive airway pressure, 505–506
complications with, 501
control mode, 503
high-frequency, 505–506
high-frequency oscillatory, 505–506
indications and goals of, 501–502
intermittent-mandatory, 503
modes of, 502–506
pressure control, 503
pressure support, 503, 505
pressure-controlled-inverse ratio, 503, 505–506
pressure-regulated volume control, 503
synchronized intermittent, 503
ventilator types in, 501–502
volume control, 503
in *Pneumocystis carinii* pneumonia, 459–460
lung damage from, lung protective strategies in, nursing implications of, 452–453
lung protective, **447–454.** See *Lung protective ventilation* (*LPV*) *strategy*(*ies*).
Mediator cascade, in acute respiratory distress syndrome, 234–235
Methemoglobinemia, from inhaled nitric oxide, 497, 507
from nitric oxide therapy, 524
Methylxanthines, for asthma, in child, 515
MIDCAB. See *Minimally invasive direct coronary artery bypass* (*MIDCAB*).
Minimally invasive direct coronary artery bypass (MIDCAB). See also *Coronary artery bypass graft* (*CABG*).
blood transfusions following, 183
critical care recovery in, perioperative, interventions for optimal, 181–183
evolution of, 179
intraoperative procedure for, 179–180
left internal mammary artery for, harvest of, 179
length of stay following, 183
monitoring following, electrocardiographic, 183
hemodynamic, 183
outcomes improvement following, **177–188**
perioperative outcomes *versus* single-vessel coronary artery bypass graft surgery, 180–181
via thoracotomy incision. See also *Coronary artery bypass graft* (*CABG*).
Minimaly invasive direct coronary artery bypass (MIDCAB), risk factor management in, cardiovascular, 183–184
Mobilization, of ventilator-dependent patient, 252
Mortality rate, clinical nurse specialist effect on, 272
MR coronary angiography, **383–404.** See also *Coronary MR angiography*.
Multicenter Automatic Defibrillator Implantation Trial (MADIT), 380–381
Mycobacteriium tuberculosis (MBT), chemoprophylaxis for, 462
clinical presentation of, 461
collaborative management for, 462
diagnosis of, 461
extrapulmonary, sites of, 461
in HIV disease, 461–462
multiple drug-resistant, 461–462

Nasogastric tubes, placement of, capnography in, 52–53
Neonatal respiratory failure, nitrous oxide therapy for, 496–498
ventilation in, **493–499**
high-frequency, 494–495
liquid, 495–496
patient-triggered, 493–494
Neurologic monitoring, of carotid artery endarterectomy patients, 204–205

Neuromuscular blockade (NMB), in head injury, 218–219
Neutrophils, in acute respiratory distress syndrome, 234–235
Nitric oxide (NO) therapy, complications with, 524
for persistent pulmonary hypertension of newborns, 496–497
complications of, 497
research on, 498
vasodilating action of, 497
in acute respiratory distress syndrome, 245
in child, 524
in mechanical ventilation, in infant and child, 507
in premature infants, with respiratory distress syndrome, 498
Nosocomial infections, aspiration pneumonia, 8
biofilm-related, 10–11
Novoste Beta-Cath system, 321, 323
in intraluminal radiation therapy, 339
Nurse practitioner. See also *Advanced registered nurse practitioner (ARNP); Clinical nurse specialist (CNS).*
role in an acute care setting, **277–282**
Nutrition, in critical illness, 227
Nutritional status, in acute respiratory distress syndrome, in child, 525
in severe respiratory distress, in child, 516

ODC. See *Oxyhemoglobin dissociation curve (ODC).*
Outcome management, definition of, 143
Outcomes-based education, critical care nursing course, SUNY, affective domain in, 287
assignments in, 288
classroom instruction in, 286–287
collaborative learning in, 286
clinical instruction in, 287–288
evaluation of, 289
examinations in, 288
future directions in, 289–290
overview of, 285
psychomotor domain in, 286–287
registered nurse students in, 288–289
for outcomes-based care delivery, local scene surveys, 284–285
national picture, 283
in a critical care nursing course, **283–290**
Outliers, clinical picture of, 109
concept of, 108–109
definition of, 109
identification of, 109
impact of, on admissions and costs, 107–108
on technology and costs, 110–112
in acute care admissions, 110
study of, 110–111
management of, approach to, 110
awareness of problem and, 112
clinical management of potential, 113–114
clinical staff readiness for, 115
education of physicians, nurses, and health team members, 113
ethics of, 112
implementation strategies for, 114–115
in short increments, 114
influence on highest resource consuming areas, **107–116**
infrastructure for, 112–113
infrastructure in, 114–115
Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment and, 112
team approach to, 113
time line for program introduction in, 114
moral and ethical dilemmas with, 109–110
patient and family in, 109–110
physician and health care team in, 110
resource utilization by, 107–108
comparison with normal patients, 108
Outpatient care, for heart failure patient, 130–131, 134–135
Oximetry, jugular venous, in severe head injury, 220–221
Oxygen pressure in arterial blood (Pao_2), 88
Oxygen saturation (Spo_2), pulse oximetry measurement of, 423–425
Oxygen toxicity, in mechanical ventilation, 447
Oxygenation, in mechanical ventilation, optimization of supply and demand and, 449
Oxygenation profiles, clinical applicaton of, case study of, 444–445
description of, 437–438
in clinical management, **437–446**
advantages of, 438
disadvantages of, 438
oxygen delivery components and, consumption, 440–441
delivery, 439–440
extraction, 441–442
mixed venous oxygen saturation, 442
oxygen content, 439
parameters in, common, 438
pulmonary, 441–445
arterial : alveolar ratio in, 443
dead space ventilation and, 443
integration with tissue oxygenation, 443–444
intrapulmonary shunt, 443
$Pao_2 : Fio_2$ in, 443
tissue, 438–439
Oxyhemoglobin, mixed venous, from pulmonary artery catheterization, 22–23, 25
Oxyhemoglobin dissociation curve (ODC), pulse oximetry and, 88, 92
Oxyhemoglobin measurement, with pulse oximeter, 89–90
contamination of, 89
transmission spectrophotometry in, 89–90, 423
Oxyhemoglobin saturation (Sao_2), pulse oximetry and, 89–90

Palliative care, for heart failure patient, 137–139
Palmaz-Schatz stent, 333–334
PAOP (pulmonary artery occlusive pressure), from pulmonary artery catheterization, 23–26
PAP (pulmonary artery pressure), from pulmonary artery catheterization, 23–24
Patient education, in heart failure management, 124, 127
Patient satisfaction, advanced registered nurse practitioner role in, 280–281
in outcomes management, of carotid endarterectomy, 203–204

Patient-triggered ventilation (PTV), in neonatal respiratory failure, assist-control, 494
complications of, 494
synchronized, 493–494
in very low birthweight infant, 494
PC-IRV. See *Pressure-controlled-inverse ratio ventilation (PC-IRV)*.
PCOT. See *Point of care testing (PCOT)*.
PCV. See *Pressure-controlled ventilation (PCV)*.
PEEP (positive end-expiratory pressure), in acute respiratory distress syndrome, 239–240
pulse oximetry and, 93, 95
Percutaneous transluminal coronary angioplasty (PTCA), disadvantages of, 311
historical perspective, 311
restenosis following, 313
Percutaneous transluminal myocardial revascularization (PTMR), background of, 327
comparison with transmyocardial revascularization, 328
follow-up process in, 331
for angina, **327–332**
indications for, 328
postprocedure regimen, 331
preprocedure workup, 329–330
baseline assessment, 329
medication regimen, 329–330
procedure for, 330
research in, 331–312
risks with, 328–329
Peristalsis, immunologic function of, 228
Permissive hypercapnia (PHC), 450–451
as lung protective strategy, 450–451
in acute respiratory distress syndrome, in children, 523
in mechanical ventilation, in infant and child, 507
in status asthmaticus, in child, 516
Persistent pulmonary hypertension (PPHN), of newborns, extracorporeal membrane oxygenation for, 497
nitrous oxide therapy for, 496–498
Pet therapy, for ventilator-dependent patient, 252
PHC. See *Permissive hypercapnia (PHC)*.
PHN. See *Persistent pulmonary hypertension (PHN)*.
Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) trial, 361
Platelet-activating factor (PAF), in acute respiratory distress syndrome, 234
Plavix (clopidogrel). See *Clopidogrel (Plavix)*.
Pneumococcal vaccine, 414
Pneumocystis carinii pneumonia
in HIV disease, clinical presentation of, 457
diagnosis of, 457–459
arterial blood gas for, 459
chest radiographs in, 457–458
in adults, 459
in children, 457
sputum samples in, 459
disseminated, 460
mechanical ventilation in, 459–460
pathogenesis of, 457
prophylaxis for, in adults, 460–461
in children, 461
treatment of, steroids in, 459
TMP/SMX in, 459
Pneumonia. See also *named, e.g. Community-acquired pneumonia (CAP)*.
causes of, 409
community-acquired, 409–414
definition of, 409
diagnosis of, 409
hospital-acquired, 414–416
in HIV disease, bacterial, 462
lymphoid interstitial, clinical presentation of, 462–463
description of, 462
diagnosis of, 463
Pneumocystis carinii, 457–461
ventilator-assisted, 416, 418–421
Pneumothorax, in acute respiratory distress syndrome, 448
Point of care testing (PCOT), **99–106**
accuracy, reliability, validity of, 101
benefits of, decreased iatrogenic blood loss, 102–103
error reduction, 103
timeliness, 101–102
cost analysis of, 103–104
definition of, 100
departmental revenue allocation and, 103
growth of, 99–100
historical perspective on, 99
impact of, 100
implementation example of, 104–105
multidisciplinary approach to, 100–101
quality control of, 103
Positive end-expiratory pressure (PEEP), as lung protective strategy, 451–452
prospective study in, 452
randomized controlled clinical trial in, 451–452
in acute respiratory distress syndrome, 239–240
in oxygenation determination, in acute respiratory distress syndrome, in children, 522
pulse oximetry and, 93, 95
Possis AngioJet system, for thrombus removal, 320
Pressors, in head injury management, 217
Pressure support ventilation, in infant and child, 503, 505
Pressure-controlled ventilation (PCV), in acute lung injury patients, as lung protective strategy, 451
in acute respiratory distress syndrome, in children, 522
in infant and child, 503–504
Pressure-controlled-inverse ratio ventilation (PC-IRV), in acute respiratory distress syndrome, 240–241
in children, 522
in infant and child, 503, 505–506
Pressure-regulated volume control ventilation, in infant and child, 503–504
PRISM (Platelet Receptor Inhibition for Ischemic Syndrome Management) trial, 361
Prone positioning, in acute respiratory distress syndrome, 241–243
in child, 524–525
in mechanical ventilation, 449, 508
PTCA (percutaneous transluminal angioplasty), 311
PTMR. See *Percutaneous transluminal myocardial revascularization (PTMR)*.
PTV. See *Patient-triggered ventilation (PTV)*.
Pulmonary angiography, capnography *versus*, 60

Pulmonary artery catheterization (PAC)
benefit of, 22
clinical application of, 22
complications with, 20–21
operator error and, 21
versus central venous access, 20–21
cost effectiveness of, 29
costs associated with, 28–29
data interpretation and, 22–25
format for, 22–23
ease in, 27–28
education for, 27–28
hemodynamic parameters in, cardiac index/output and, 23
central venous pressure and, 23
mixed venous oxyhemoglobin, 22–23
pulmonary artery occlusive pressure and, 23
pulmonary artery pressure and, 23–24
stroke volume/index and, 23
systemic and pulmonary resistance, 24
in hemodynamic monitoring, **19–31**
information obtained with, 22
performance of, manufacturers' claims and, 21
profile from, 238
safety and accuracy of, 20–21
technical aspects of, 26–27
treatment and, 25–26
use of, recommendations for, 19
research in, 20
Pulmonary artery occlusive pressure (PAOP), from pulmonary artery catheterization, 23–26
Pulmonary artery pressure (PAP), from pulmonary artery catheterization, 23–24
Pulmonary lymphoid hyperplasia, in HIV disease, 462–463
Pulmonary vascular resistance (PVP), from pulmonary artery catheterization, 24
Pulse oximetry, **87–98**
accuracy of, 89–90
ambient light and, 90–91
anemia and, 91
motion artifact and, 90
peripheral vasoconstriction and, 91
sensor technology and, 90
skin pigmentation and nail polishes and, 91
advantages of, 87
alveolar oxygen tension and, 88
arterial oxygen saturation and, 88–89
clinical applications of, assessment of respiratory function, case histories of, 93–94
continuous pulmonary monitoring, 93
intrapulmonary shunting assessment, 94–95
combination with capnography, 102–103
cost implications of, 96
description of, 424
dysrhythmias and, 93
education associated with, 96
guidelines for using, 415–426
hemoglobin and, 88, 424
history of, 423–424
in adjustment of forced inspiratory oxygen, 95
in adjustment of positive end-expiratory pressure, 93, 95
intrapulmonary shunt and, 88–89
light absorption spectra for hemoglobin, 424
oxygen delivery and, 95
oxyhemoglobin dissociation curve and, 88, 92–93
oxyhemoglobin saturation and, 89–90
pressure of oxygen in arterial blood and, 88
pulse oximeters in, 425
relationship of partial pressure of oxygen and oxygen hemoglobin saturation, 92–93
reliability of, maximizing of, 91
respiratory physiology overview and, 87–93
safety issues and, 90
uses of, 426
wavelengths of light in, 424
PVP (pulmonary vascular resistance), from pulmonary artery catheterization, 24

Qs/Qt. See *Intrapulmonary shunting (Qs/Qt)*.

RA (rotational atherectomy) catheter, 315–316
Radiation, beta, 338–339, 345–346
gamma, 338, 344–345
Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE), 333, 361
RAPPORT (ReoPro and Primary PTCA Organization and Randomized Trial), 359
Recombinant tissue plasminogen factor (rt-PA), for stroke, 262–263
ReoPro (abciximab). See *Abciximab (ReoPro)*.
ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT), 359
Resource utilization, by outliers, 107–108
reduction of, 45, 59–60
Respiratory failure, **481–491**
acute *vs.* chronic, 481–482
artificial ventilation in, 482
complications of, 483
decision-making in, counseling in, 484
difficult, 483
for withdrawal, 484
patient and family in, 483–484
etiology of, 481
hypercapnic failure, 481
post-ICU care transitioning in, 484
continuum of care in, 485–488
pressure support ventilation in, 485
to chronic care facilities, 487
to home, 487–488
case history, 488–489
to intermediate care units, 485
to medical-surgical units, 486
to subacute and skilled nursing facilities, 486
symptoms of, 483
Respiratory monitoring. See also *named modality, e.g., Capnography*.
capnography in, 426–430
continuous airway pressure monitoring in, 428, 431–433
impedance monitoring in, 432–433
noninvasive, **423–435**
pulse oximetry in, 423–426
Restenosis, brachytherapy for, **333–348.** See also *Brachytherapy, for restenosis; Intraluminal radiation therapy*.
cell life cycle and, 335
defined, 334

Restenosis (*Continued*)
directional coronary atherectomy for, 311–313
interventions for, studies of, 333–334
Palmaz-Schatz stent for, 312–313, 317–320, 333–334
radiation trials, 320–321, 323
theory of, 313–315
RESTORE (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis) trial, 333, 361
Resuscitation, in end-stage heart failure, 138
Reveal insertable loop recorder (RILR) system, 299–301
advantages of, 300–301
description of, 299–300
design of, 299–300
in syncope diagnosis, 299–301
Rotational atherectomy (RA) catheter, for problem coronary lesions, 315–316
for stent restenosis, 315–316

Schneider Wallstent Endovascular prosthesis, 320
Scripps Coronary Radiation to Inhibit Proliferation Post Stenting (SCRIPPS) trial, 321
Sedation, in head injury, 218
in status asthmaticus, in child, 516
Sedation and neuromuscular blockade, for intubation, 214
for severe head injury, 218–219
Severe head injury, Advanced Life Support evaluation in, 212
barbiturates in, 221
cerebral physiology in, 210
cost of, 209
Glasgow Coma Scale in, 211
Guidelines for the Management of Severe Head Injury and, 209–210
hypercapnia in, 211
hyperemia in, 211
hyperventilation in, 219–220
hypotension in, 211–212
hypothermia in, 221–222
hypoxia in, 211–212
incidence of, 209
initial resuscitation in, 212–215
intubation in, 212, 214
management strategies for improving outcome of, **209–225**
mannitol in, 219
neuromuscular blockade in, 218–219
oximetry in, jugular venous, 220–221
primary, 210
sedation and analgesia in, 218
volume resuscitation in, 214–215
Severe head trauma, cerebral perfusion pressure and, enhancement of, 215, 217–218
intracranial hypertension in, intracranial pressure monitoring for, 215
management of, 215–216
Small intestine, function of, normal, 227–228
Sotalol, for ventricular tachycardia, 378
STARS (STent Antithrombotic Regimen Study), 317–318
Status asthmaticus, definition of, 511
in children, fluid management in, 516
helium gas with oxygen for, 516
magnesium sulfate for, 515–516
patient education and follow-up care and, 516–517
sedation in, 516
supportive care and management in, 516
STent Antithrombotic Regimen Study (STARS), 317–318
STent REStenosis Study (STRESS) trial, 312–313, 317, 333–334
Stent(s), anticoagulation regimens with, 317–318
balloon expandable, 318–319
Boston Scientific Radius, 319
coronary, anticoagulation with, 317–318
Palmaz-Schatz, 312–313
post coronary artery bypass grafting, 395
radioactive, 339
Schneider Wallstent Endovascular prosthesis, 320
self-expanding, 319–320
Stomach, function of, normal, 227
STRESS. See *STent REStenosis Study (STRESS) trial*.
Stroke. See also *Stroke team*.
ischemic, and thrombolytic therapy, 262
Stroke team. See also *Stroke*.
emergency department, critical care nursing and, 267
emergency medical services training and, 263–264
laboratory and, 266–267
neurology and neurosurgery departments and, 266
nurses on, 264–265
pharmacy and, 266–267
physicians on, 265–266
radiology and, 266
Stroke volume/index (SV/SI), from pulmonary artery catheterization, 23, 25
Subendocardial resection, for tachyarrhythmias, ventricular, 303
Suctioning, subglottic, 8–9
practical considerations in, 11
Sudden cardiac death (SCD), incidence of, 303
pharmacological management of, 303
surgical management of, 303
Sulcrafate, in ventilator-associated pneumonia, 420
Surfactant, in acute respiratory distress syndrome, in child, 523
SvO_2. See *Continuous mixed venous oxygen (SvO_2) monitoring*.
Synchronized intermittent mandatory ventilation, in infant and child, 503–504
Syncope, defined, 297
diagnosis of, 297–299. See also *Reveal Implantable loop recorder (RILR) system*.
ECG strip in, 298–299
electrophysiology studies in, 298
loop monitors in, external, 297–298
Reveal insertable loop recorder (RILR) in, 299–301
tilt table testing in, 298
etiology of, 297–298
implantable loop monitor and, **297–301**
morbidity and mortality with, 297
vasovagal, 298
Systemic vascular resistance (SVR), from pulmonary artery catheterization, 24

TEC (transluminal extraction catheter), 316–317
Technology, assessment of, 63–64
framework for, 63–64
research analysis and, 63–64

assessment template for, 2
clinical and cost impact of, in acute and critical care, **1–5**
economic impact of, 5
education associated with, for advanced applications, 4–5
levels of, 4
providers of, 3–4
in acute care, 1–2
in critical care, 1
introduction into practice, 3
physicians and managers of, expectations of, 5
problems with use of, 1–3
abuse, 2
education, 3
role of, in cost control, 107
use of, optimal, 107
outliers and, 110–112
Telemetry monitoring, alarm systems in, 79–81
arrhythmia detection in, 79
centralized, implications for, 81–82
cost effectiveness of, 83–84
guidelines for, 81–82
in acute and critical care, **77–85**
monitor watchers in, 81–82, 84
network example of, 77–78
patient outcomes with, 82
QRS detection in, 78–79
safety and, 79–81
arrhythmia alarms for, 79–80
electrical, 80–81
system components for, antennae, 78
filters for QRS detection, 78–79
monitors, 78
transmitters, 77–78
usability of, access to information collected, 83
flexibility of system and, 83
system-user interface and, 82–83
Thrombolysis in Myocardial Infarction (TIMI) trial, 359
Thrombus, removal devices for, 320–321
Ticlopidine (Ticlid), 364–365
anticoagulation with, post stent, 317–318
TIMI (Thrombolysis in Myocardial Infarction) trial, 359
Tirofiban (Aggrastat), 360–362
Tissue oxygenation, mixed venous oxygen monitoring and, 37–39
TMR (transluminal myocardial revascularization), 377
Torsades de pointes, 376
Tracheal stenosis, prevention of, 12–13
Tracheal tubes, cuffs on, injuries from, 11–13
pressure monitors for, 13
Transluminal extraction catheter (TEC), for thrombus and plaque removal, 316–317
Transluminal myocardial revascularization (TMR), 377. See also *Percutaneous transluminal myocardial revascularization (PTMR)*.
Transmission spectrophotometry, in pulse oximetry, 89–90
Turn around time (TAT), of point of care testing, 101–102

VAP (ventilator associated pneumonia), 8–9
Ventilation/perfusion (V/Q) scans, capnography *versus*, 60
Ventilator associated pneumonia (VAP), 8–9
Ventilator dependence. See also *Ventilator-dependent patient*.
contributing factors in, 249–250
Ventilator-associated pneumonia (VAP), 416, 418–421
American Thoracic Society practice guidelines in, 419
definition of, 416, 418
diagnosis of, 418
mortality rates in, 416
nursing measures in, 420–421
outcomes in, 419
predisposing factors for, 419
prevention of, 419–421
recommended and nonrecommended interventions in, 419–420
rates of, 416, 418
treatment of, 419
antibiotics in, 417
Ventilator-dependent patient. See also *Ventilator dependence*.
definition of, 249
in-hospital unit for, 250–251
outcomes of, 253–259
case study, 258–259
decannulation, 253–254
long-term care facilities, 254
successful outcomes for, **249–260**
teaching home care, 254–257
withdrawal of care and, 254
progressive pulmonary care unit for, 250–251
advanced practice nurse in, 250–251
care plan in, multidisciplinary, 251
communication and, 251–252
diversional activities and, 252
family and, 252–253
mobilization and, 252
pet therapy and, 252
psychosocial support and, 252–253
strategies in, 251–252
weaning of, successful, 250
Ventilatory strategies, in infant and child, **501–509.** See also *Mechanical ventilation*.
lung protective, **477–454**
Ventricular arrhythmias, electrophysiologic studies, and devices, **375–382**
Ventricular tachycardia/ventricular fibrillation (VT/VF), electrophysiology testing and, 376–377
evaluation of, 375–376
monomorphic and polymorphic, 376
subendocardial resection for, 303
treatment of, 377–381
ablative procedures, catheter, 377–378
surgical, 377
implantable cardioverter defibrillator *versus* antiarrhythmics in, 378–380
pharmacologic, 378
prophylactic, 379–381
triggers for, 375–376
Volume control ventilation, in infant and child, 503–504
Volume resuscitation, in head trauma, hypertonic saline solutions for, 214–215
isotonic crystalloid solutions for, 214
Volutrauma, in mechanical ventilation, animal data and, 448

VT/VF. See *Ventricular tachycardia/ventricular fibrillation (VT/VF).*

Weaning, from long-term mechanical ventilation
clinical pathway development for, 468
best practice indicators for, 468–471
managment and monitoring in, 472–483
multidisciplinary input in, 468–471
outcomes manager in, 471–472
stages of weaning in, 468
testing and revision in, 472–473
outcomes approach to, 466
outcomes-managed *versus* standard care, 466
protocol development for, 473–474
endurance conditioning in, 474–475
gentle trials in, 475–477
intolerance definition for, 475
respiratory muscles in, fatigue and and rest, 474
rest definition for, 475
sprint trials in, 475–477
strengthening conditioning in, 474
special care unit *versus* ICU, 466
the science of, 466–467
pathways and protocols that work, **465–479**
Withdrawal of care, for ventilator-dependent patient, 254
Work of breathing, decreasing of, 13–15
increase in, 13–14